- Report
- August 2022
- 285 Pages
Global
From €9067EUR$9,500USD£7,597GBP
- Drug Pipelines
- September 2021
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- February 2024
- 204 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- May 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- April 2023
- 117 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- August 2024
- 93 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- January 2025
- 93 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
Gemcitabine is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It is a nucleoside analog, meaning it works by interfering with the growth of cancer cells. Gemcitabine is typically used in combination with other drugs, such as cisplatin, to treat non-small cell lung cancer (NSCLC). It is also used to treat small cell lung cancer (SCLC). Gemcitabine is generally well-tolerated, with few side effects.
Gemcitabine is a widely used drug in the treatment of lung cancer. It is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and SCLC. It is also approved for use in combination with other drugs for the treatment of advanced NSCLC.
The market for Gemcitabine is highly competitive, with many companies offering the drug. Some of the major players in the market include Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, and Roche. Other companies offering the drug include AstraZeneca, Novartis, and Teva Pharmaceuticals. Show Less Read more